NasdaqCM:EYEN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	35	-24	-19	5	2
12/31/2025	12	-42	-37	-27	4
12/31/2024	4	-32	-36	-34	4
3/31/2024	0	-32	-30	-27	N/A
12/31/2023	0	-27	-28	-24	N/A
9/30/2023	0	-25	-27	-23	N/A
6/30/2023	N/A	-25	-26	-24	N/A
3/31/2023	N/A	-26	-25	-24	N/A
12/31/2022	N/A	-28	-26	-25	N/A
9/30/2022	10	-19	-27	-26	N/A
6/30/2022	10	-17	-25	-24	N/A
3/31/2022	12	-15	-26	-24	N/A
12/31/2021	14	-13	-22	-21	N/A
9/30/2021	6	-20	-11	-10	N/A
6/30/2021	6	-19	-7	-6	N/A
3/31/2021	4	-20	-6	-5	N/A
12/31/2020	2	-20	-7	-6	N/A
9/30/2020	N/A	-21	-16	-16	N/A
6/30/2020	N/A	-20	-18	-18	N/A
3/31/2020	N/A	-21	-19	-19	N/A
12/31/2019	N/A	-21	-19	-19	N/A
9/30/2019	N/A	-22	-19	-19	N/A
6/30/2019	N/A	-22	-19	-19	N/A
3/31/2019	N/A	-20	-17	-17	N/A
12/31/2018	N/A	-17	-13	-13	N/A
9/30/2018	N/A	-13	-11	-11	N/A
6/30/2018	N/A	-10	-8	-8	N/A
3/31/2018	N/A	-7	-6	-6	N/A
12/31/2017	N/A	-5	N/A	-5	N/A
9/30/2017	N/A	-4	N/A	-4	N/A
12/31/2016	N/A	-4	N/A	-3	N/A

アナリストによる今後の成長予測

収入対貯蓄率: EYEN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: EYEN今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: EYEN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: EYENの収益 ( 56.9% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: EYENの収益 ( 56.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EYENの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Eyenovia 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates decrease by 32%, EPS upgraded

Consensus revenue estimates increase by 40%

Consensus revenue estimates increase by 27%

Consensus revenue estimates increase by 32%

Price target decreased by 8.6% to US$10.67

Consensus revenue estimates increase by 33%

Recent updates

New major risk - Shareholder dilution

Consensus revenue estimates decrease by 32%, EPS upgraded

Eyenovia, Inc. to Report Q1, 2024 Results on May 15, 2024

Eyenovia, Inc., Annual General Meeting, Jun 12, 2024

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension

New major risk - Share price stability

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

Consensus revenue estimates increase by 40%

Consensus revenue estimates increase by 27%

Consensus revenue estimates increase by 32%

Eyenovia, Inc. to Report Q4, 2023 Results on Mar 18, 2024

Price target decreased by 8.6% to US$10.67

Consensus revenue estimates increase by 33%

Consensus revenue estimates increase by 33%

Is Eyenovia (NASDAQ:EYEN) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 54%

New minor risk - Share price stability

High number of new directors

Eyenovia, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production

Is Eyenovia (NASDAQ:EYEN) Using Debt In A Risky Way?

Eyenovia, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Is Eyenovia (NASDAQ:EYEN) Using Debt Sensibly?

Insider recently bought US$234k worth of stock

Eyenovia, Inc., Annual General Meeting, Jun 27, 2023

Eyenovia, Inc. Announces FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasis

Eyenovia, Inc. to Report Q1, 2023 Results on May 11, 2023

Co-Founder recently sold US$300k worth of stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

No longer forecast to breakeven

No longer forecast to breakeven

Eyenovia, Inc. Showcases Microdose Array Print (MAP™) Technology At CES 2023 in Las Vegas

Eyenovia, Inc. Announces Positive Results from a Research Study

Forecast to breakeven in 2025

High number of new directors

Eyenovia Aims to Revolutionize Ophthalmology Devices with Microdose Array Print (Map) Technology

Eyenovia, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation

Eyenovia, Inc. Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President, Effective January 1, 2023 and Julia Haller Steps Down from its Board of Directors

Price target decreased to US$14.33

Third quarter 2022 earnings released: US$0.21 loss per share (vs US$0.21 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.21 loss per share (vs US$0.21 loss in 3Q 2021)

Eyenovia, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Does Eyenovia (NASDAQ:EYEN) Have A Healthy Balance Sheet?

Eyenovia, Inc Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia

Eyenovia gains as H.C. Wainwright initiates with Buy on pipeline potential

Eyenovia, Inc. Announces Retirement of Ken Lee as Lead Independent Director

Eyenovia's Novel Optejet® Dispenser Puts People's Eyes First

First half 2022 earnings released

Eyenovia, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Eyenovia, Inc. Announces Board Changes

Eyenovia names Michael Rowe as new CEO

Eyenovia Appoints Bren Kern as SVP of Manufacturing and Operations

Eyenovia, Inc. Announces Executive Changes

Insider recently bought US$165k worth of stock

Eyenovia Inc. Announces Transition of Sean Ianchulev from CEO to Non-Executive Chairman of the Board

Price target increased to US$17.50

Insider recently bought US$113k worth of stock

Eyenovia, Inc. to Report Q1, 2022 Results on May 12, 2022

Eyenovia, Inc., Annual General Meeting, Jun 16, 2022

Less than half of directors are independent

Consensus revenue estimates increase by 41%

New Forecasts: Here's What One Analyst Thinks The Future Holds For Eyenovia, Inc. (NASDAQ:EYEN)

Earnings Beat: Eyenovia, Inc. (NASDAQ:EYEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Eyenovia, Inc. to Report Q4, 2021 Results on Mar 28, 2022

Eyenovia: I Can See You Better - Now

Insider recently bought US$144k worth of stock

Insider recently bought US$107k worth of stock